Compare AEYE & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEYE | RNXT |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 79.4M |
| IPO Year | 2011 | 2021 |
| Metric | AEYE | RNXT |
|---|---|---|
| Price | $12.32 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $17.33 | $7.13 |
| AVG Volume (30 Days) | 337.9K | ★ 360.8K |
| Earning Date | 10-26-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.56 | 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,311,000.00 | $1,123,000.00 |
| Revenue This Year | $8.43 | $244.84 |
| Revenue Next Year | $10.19 | $195.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 14.52 | ★ 2511.63 |
| 52 Week Low | $5.31 | $0.70 |
| 52 Week High | $14.68 | $2.59 |
| Indicator | AEYE | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 65.28 | 36.64 |
| Support Level | $6.03 | $1.09 |
| Resistance Level | $14.68 | $1.30 |
| Average True Range (ATR) | 1.20 | 0.12 |
| MACD | 0.30 | -0.00 |
| Stochastic Oscillator | 70.62 | 36.72 |
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.